Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer
Abstract
The overall objective of this project is to study the safety, immunologic response and clinical effects of vaccinating breast cancer patients with dendritic cell (DC)/tumor fusions in conjunction with IL-12. Studies performed in Task 1 have shown that the DC/breast tumor fusions are effective in (1) stimulating cytokine production, and (2) inducing tumor-specific T cell responses. Work performed over the past year has extended these studies by further defining the effects of stimulation with IL-12, Toll-like receptor agonists, CpG oligodeoxynucleotide and CD3/CD28 ligation as approaches that could be used to enhance effectiveness of the DC/breast tumor fusion vaccine. The results support our original hypothesis that IL-12 should be used in conjunction with the DC/breast tumor fusion vaccine in clinical trials. Our clinical protocol has been approved by the FDA, the NCI Clinical Trials Evaluation Program and the Dana-Farber/Harvard Cancer Center IRB. Lengthy delays in the DOD human use approval process have necessitated NCI recertification of the IL-12 before we can begin the trial.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2006
- Accession Number
- ADA459218
Entities
People
- Donald W. Kufe
Organizations
- Dana–Farber Cancer Institute